Skip to main
BCAX

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 50%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Bicara Therapeutics Inc. is showing a strong positive outlook due to the superior overall response rates (ORR) of its lead product, ficerafusp alfa, compared to key competitors like Keytruda, with significantly higher ORR metrics noted. The combination therapy of ficerafusp alfa and Keytruda demonstrated a median progression-free survival (mPFS) of 9.9 months and a median overall survival (mOS) of 21.3 months, which are favorable compared to existing first-line treatments. These promising clinical outcomes highlight Bicara's potential to deliver transformative therapies for patients with solid tumors, indicating robust future growth prospects.

Bears say

Bicara Therapeutics Inc. reported a net loss of $0.50 per share for the second quarter of 2025, closely aligning with the previous estimate of $0.51 per share, indicating persistent financial challenges. The company faces numerous risks, including potential negative clinical results for ficerafusp alfa, delays in advancing this therapy into registrational trials, and hurdles in obtaining timely regulatory approvals, which could further impede its progress and revenue generation. Additionally, the projected full-year net loss for 2025 has been adjusted to $2.27 per share, showing only a slight improvement from an earlier estimate of $2.31 per share, reflecting ongoing concerns regarding its financial outlook.

BCAX has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 50% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 6 analysts, BCAX has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.84, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.84, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.